News | 31 May 2012
TOKYO, May 31, 2012 /PRNewswire via COMTEX/ -- Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year. RECOURSE is a randomized, ...
Click on the link to read the full article at MarketWatch (press release)
(This link will open in a new window)